178 completed. 178 Phase 3, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 178 | Completed 178 |
| Phase 2 | 13 | Completed 13 |
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension QLS-111-FDC, Latanoprost (0.005%) - OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension | Phase 2 / Phase 3 | Completed | Qlaris Bio, Inc. | 64 | 2026-03-18 | 2026-07-29 |
| Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution - Ocular Hypertension, Open Angle Glaucoma | Phase 3 | Completed | Alcon Research | 489 | 2025-09-02 | 2026-04-21 |
| The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Placebo - Pseudophakic Bullous Keratopathy, Glaucoma | Phase 2 / Phase 3 | Completed | University Hospital Dubrava | 50 | 2025-05-12 | 2026-09-09 |
| Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® ) - Glaucoma, Neuroprotection | Phase 3 | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 40 | 2024-01-27 | 2025-05-01 |
| Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution NCX 470, Placebo - Open Angle Glaucoma | Phase 2 / Phase 3 | Completed | Nicox Ophthalmics, Inc. | 18 | 2023-12-12 | 2025-09-08 |
| OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects OPC-1085EL, 0.005% Latanoprost - Open Angle Glaucoma or Ocular Hypertension | Phase 3 | Completed | Otsuka Beijing Research Institute | 204 | 2022-09-27 | 2025-03-27 |
| A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension STN1012600 ophthalmic solution 0.002%, Latanoprost ophthalmic solution 0.005% - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Santen Pharmaceutical Co., Ltd. | 325 | 2022-08-09 | 2023-12-05 |
| A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension STN1012600 ophthalmic solution 0.002%, STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5% - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Santen Pharmaceutical Co., Ltd. | 131 | 2022-08-08 | 2024-07-15 |
| Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma XEN45 (Glaucoma Gel Stent) - Open-Angle Glaucoma | Phase 3 | Completed | AbbVie | 74 | 2022-07-22 | 2026-02-27 |
| Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients Bimatoprost Ophthalmic - Glaucoma, Ocular Hypertension | Phase 3 | Completed | Laboratoires Thea | 684 | 2022-06-22 | 2024-07-18 |
| A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension Brinzolamide ophthalmic suspension, Azopt® - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Sun Pharmaceutical Industries Limited | 599 | 2021-12-20 | 2024-01-18 |
| Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) - Glaucoma, Open-Angle | Phase 3 | Completed | Mankind Pharma Limited | 310 | 2021-10-02 | 2022-12-13 |
| To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension - Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Completed | Padagis LLC | 447 | 2021-05-28 | 2025-04-02 |
| BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension BREMEN eye drops, Combigan® - Ocular Hypertension, Primary Open-angle Glaucoma | Phase 3 | Completed | EMS | 406 | 2021-02-01 | 2024-02-20 |
| Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension Netarsudil ophthalmic solution 0.02%, Ripasudil hydrochloride hydrate ophthalmic solution 0.4% - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Aerie Pharmaceuticals | 245 | 2020-11-30 | 2023-02-27 |
| MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension NCX 470 0.1%, Latanoprost 0.005% - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Nicox Ophthalmics, Inc. | 696 | 2020-11-09 | 2025-09-08 |
| A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension Bimatoprost SR, LUMIGAN - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | AbbVie | 37 | 2020-06-11 | 2023-06-08 |
| Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial) - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Nicox Ophthalmics, Inc. | 691 | 2020-06-01 | 2025-06-24 |
| To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension - Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Completed | Padagis LLC | 495 | 2019-06-24 | 2023-03-06 |
| A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension DE-130A, Xalatan®, DE-130A/DE-130A - Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease | Phase 3 | Completed | Santen SAS | 386 | 2019-04-10 | 2024-05-28 |
Showing 20 of 178. Sign in to see all of them.
Ocular Hypertension (128) · Glaucoma, Open-Angle (115) · Hypertension (9) · Glaucoma, Neovascular (5) · Cataract (3) · Exfoliation Syndrome (3) · Glaucoma, Angle-Closure (3) · Pterygium (3) · Choroidal Neovascularization (1) · Corneal Edema (1) · Diabetic Retinopathy (1) · Eye Diseases (1) · Fibrosis (1) · Hydrophthalmos (1)
Eye Diseases (177) · Ocular Hypertension (50) · Cardiovascular Diseases (10) · Vascular Diseases (10) · Uveal Diseases (4) · Conjunctival Diseases (3) · Iris Diseases (3) · Lens Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Retinal Degeneration (2) · Retinal Diseases (2) · Amino Acid Metabolism, Inborn Errors (1)
Timolol (35) · Latanoprost (33) · Travoprost (22) · Ophthalmic Solutions (21) · brinzolamide (13) · Bimatoprost (10) · Brimonidine Tartrate (10) · netarsudil (9) · Xalacom (8) · Duotrav (6) · dorzolamide (6) · dorzolamide-timolol combination (6) · BID protein, human (5) · Brimonidine Tartrate, Timolol Maleate Drug Combination (5) · Solutions (5)
Alcon Research (39) · Allergan (16) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (10) · Santen Pharmaceutical Co., Ltd. (10) · Aerie Pharmaceuticals (8) · Pro Top & Mediking Company Limited (6) · AbbVie (5) · Glaukos Corporation (5) · Merck Sharp & Dohme LLC (5) · Santen Oy (5) · Bausch & Lomb Incorporated (4) · Laboratoires Thea (4) · Nicox Ophthalmics, Inc. (3) · Santen Inc. (3) · Sun Pharma Advanced Research Company Limited (3)
United States (71) · Japan (15) · Germany (12) · United Kingdom (12) · France (11) · Australia (9) · China (9) · Russia (9) · Canada (8) · Italy (8) · Spain (8) · Belgium (7) · Denmark (7) · Poland (7) · Czechia (6)
Theresa Heah, MD (4) · Auli Ropo, M.D. (2) · James Teague, BS, Sr. Clinical Manager (2) · Jason Vittitow (2) · Jeff Wells, PharmD, MBA (2) · Margot Goodkin (2) · Marlene R Moster, MD (2) · Pamela Smith, B.S. (2) · Theresa Heah, MD, MBA (2)
PMID 10937547, PMID 19427617, PMID 35943114, PMID 36912740, PMID 17122118, PMID 29194198, PMID 32166538, PMID 35643967, PMID 36378864, PMID 38985408, PMID 39240530, PMID 17459480, PMID 18289898, PMID 18414108, PMID 18534052, PMID 18538406, PMID 19365194, PMID 19683191, PMID 19850848, PMID 20142538, PMID 20212196, PMID 20346127, PMID 20828829, PMID 20874498, PMID 21735753, PMID 21851642, PMID 22310086, PMID 22814041, PMID 23579344, PMID 24667994, PMID 24794283, PMID 25019269, PMID 25430900, PMID 25447269, PMID 25613811, PMID 25826644, PMID 26875002, PMID 27210275, PMID 27292765, PMID 27457469, PMID 2788589, PMID 29057117, PMID 29680880, PMID 31981106, PMID 32089329, PMID 32533949, PMID 32572719, PMID 33250082, PMID 33330958, PMID 33330959
2014 (2), 2015 (2), 2018 (2), 2008 (1), 2009 (1), 2023 (1), U10EY009307 (1), U10EY009341 (1)